How can radiopharmaceutical therapies reach their full potential? Improving dose reporting and phase I clinical trial design Journal Article
| Authors: | Kiess, A. P.; O'Donoghue, J.; Uribe, C.; Bodei, L.; Hobbs, R. F.; Hesterman, J.; Kesner, A. L.; Sgouros, G.; on behalf of the RPT-TEC group |
| Article Title: | How can radiopharmaceutical therapies reach their full potential? Improving dose reporting and phase I clinical trial design |
| Keywords: | note; research design; methodology; antineoplastic agent; radiopharmaceuticals; neoplasm; neoplasms; nephrotoxicity; radiotherapy dosage; food and drug administration; prostate specific membrane antigen; myelodysplastic syndrome; radioactive iodine; biological activity; dosimetry; radiopharmaceutical agent; xerostomia; external beam radiotherapy; maximum tolerated dose; clinical trials, phase i as topic; adverse drug reaction; phase 1 clinical trial (topic); single photon emission computed tomography; acute myeloid leukemia; procedures; humans; human; xerophthalmia; vipivotide tetraxetan lutetium lu 177; oxodotreotide lutetium lu 177 |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 15 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-05-20 |
| Start Page: | 1734 |
| End Page: | 1737 |
| Language: | English |
| DOI: | 10.1200/jco.23.01241 |
| PUBMED: | 38484205 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Note -- Source: Scopus |
